1. Report Overview
1.1 Biobanking for Medicine: World Market Review 2017 and Global Segmentation
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Key Questions Answered by This Analytical Report
1.5 Who is This Report For?
1.6 Methodology
1.7 Frequently Asked Questions (FAQ)
1.8 Associated Visiongain Reports
1.9 About Visiongain
2. Introduction to Biobanking and its Applications
2.1 Defining the Human Tissue Banking Market for the Scope of this Report
2.2 The Stem Cell Banking Market – Our Breakdown
2.3 What is Biobanking?
2.4 Main Features of Biobanks
2.5 What Processes are Involved in Biobanking?
2.6 Classification of Biobanks: Tissue Type, Volunteer Group and Ownership Classification Models
2.6.1 Volunteer Group: General vs. Disease Population
2.6.2 Ownership Structure: Public vs. Private
2.7 The Guidelines and Standards for Biobanking
2.8 Laws and Regulations for Biobank-Based Research
2.8.1 HIPAA Amendments
2.9 Biobanking and the Pharmaceutical Industry
2.9.1 Biobanking in Research, Drug Discovery and Development
2.9.1.1 Biobanking – Facilitates Genetic Epidemiology Studies
2.9.1.2 Novel Drug Discovery through Better Understanding of Disease Pathways
2.9.1.3 Biomarker Discovery in Drug Development
2.9.2 Biobanking for Therapeutic Purposes
2.9.3 Biobanking in Clinical Trials
3. Biobanking for Medicine: World Market 2017 to 2027
3.1 The World Biobanking for Medicine Market in 2017
3.2 Biobanking for Medicine: Research vs. Therapeutics in 2022 and 2027
3.3 World Biobanking for Medicine Market: Overarching Revenue Forecast 2017 to 2027
3.4 Biobanks Stored More Than 1.5 Billion Specimens in 2017
3.5 The Biobanking for Medicine Market by Sector: Grouped Revenue Forecasts 2017 to 2027
3.6 Biobanking for Research: Mostly Non-Profit
3.6.1 Biobanking for Research: Revenue Forecast 2017 to 2027
3.6.2 Driving Forces: Outweighs Restraints on the Biobanking Industry for Research
3.7 Biobanking for Future Therapeutic Use: Is It Too Commercial?
3.7.1 Arguments against Commercial Stem Cell Banking for Therapeutic Uses
3.7.2 Biobanking for Future Therapeutic Use: Revenue Forecast 2017 to 2027
3.7.3 Driving and Restraining Forces Influencing the Biobanking Market for Therapeutic Applications, 2017 to 2027
4. Biobanking for Research Purposes
4.1 Breakdown of Biobanking for Research Market by Tissue Type, 2017
4.2 Biobanking for Research in 2022 and 2027: Comparison by Tissue Type
4.3 Biobanking for Research by Tissue Type: Grouped Revenue Forecasts 2017 to 2027
4.4 How Many Specimens are Biobanked for Research?
4.5 The Human Tissue Banking Market for Research in 2017
4.6 The Human Tissue Banking Market for Research: Revenue Forecast 2017 to 2027
4.7 The Human Tissue Banking Market: Commercial vs. Public Sector
4.7.1 Commercial Human Tissue Banks: Revenue Forecast 2017 to 2027
4.7.2 Public Sector Human Tissue Banks: Revenue Forecast 2017 to 2027
4.8 The Stem Cell Banking Market for Research in 2017
4.9 The Stem Cell Banking Market for Research: Revenue Forecast 2017 to 2027
4.9.1 R&D- Growing Interest Towards iPSCs
4.10 Banking of Other Biologics Specimens for Research in 2017
4.11 Banking of Other Biologic Specimens for Research: Revenue Forecast 2017 to 2027
5. Stem Cell Banking for Future Therapeutic Use
5.1 Stem Cell Banking for Therapeutic Use in 2017: A Breakdown by Stem Cell Type
5.2 Stem Cell Banking for Therapeutic Use by Stem Cell Type: Comparison of Revenue and Market Share, 2022 and 2027
5.3 Stem Cell Banking for Therapeutic Use by Stem Cell Type: Grouped Revenue Forecasts
5.4 How Many Stem Cells Are Biobanked Each Year?
5.5 The Umbilical Cord Blood Banking Market in 2017
5.5.1 Private vs. Public Cord Blood Banking
5.5.2 Umbilical Cord Blood Banking: The Controversies
5.6 The Umbilical Cord Blood Banking Market: Revenue Forecast 2017 to 2027
5.7 The Adult Stem Cell Banking Market in 2017
5.8 The Adult Stem Cell Banking Market: Revenue Forecast 2017 to 2027
6. Leading National Markets 2017 to 2027
6.1 The Geographical Footprint of Biobanking
6.1.1 Biobanking in Europe: Leading the World with Biobanking Networks and Infrastructure
6.1.2 Biobanks in the US: A Fragmented Picture
6.1.3 Biobanking in Asia: A Region Fast Gaining Prominence
6.2 Biobanking for Medicine: The US Led the Way in 2017
6.3 The Leading National Markets: Grouped Revenue Forecasts 2017 to 2027
6.4 How Will Regional Market Shares Change to 2027?
6.5 The US Biobanking Market 2017 to 2027: Diversifying and Expanding
6.6 The Top European Biobanking Markets 2017 to 2027: Leading the Way in Biobanking Infrastructure
6.6.1 Germany: An Advanced Industry with 74 Biobanks Associated with the BBMRI
6.6.2 France: Restrictions on Private Stem Cell Banking Limit the Market
6.6.3 Italy: Is the Limited Private Stem Cell Banking Market Off-Set by Strong Biobanking Networks for Research?
6.6.4 UK: Limited Presence of Biobanking Networks
6.6.5 Spain: Controversy Between Private and Public Umbilical Cord Blood Banks
6.6.6 The Netherlands is Characterised by Comprehensive Biobanking Networks
6.7 The Japanese Biobanking Market 2017 to 2027: A High Level of Government Investment Drives Growth
6.8 The Biobanking Industry in the BRIC Countries: High Growth and Increasing Market Share between 2017 and 2027
6.8.1 The Chinese Biobanking Market 2017 to 2027: The High Rate of Growth Will Continue
6.8.2 The Indian Biobanking Market 2017 to 2027: Set to Become the Leading Market for Private Stem Cell Banking?
6.8.3 The Brazilian Biobanking Market 2017 to 2027: Will New Regulations Drive or Restrain the Market?
6.8.4 Russia: Ban on the Import and Export of Human Tissue and Genetic Information Restricts the Market, But Can This Be Overcome from 2017 to 2027?
7. Technology for Biobanking: Systems, Software, Consumables, and Services Associated with Biobanking
7.1 The Biobanking-Associated Market: Overview
7.2 Systems Technology: Fully Automated Handling
7.2.1 Automated Liquid Handling Systems
7.2.2 Frozen Aliquoting: Patented Technology from CryoXtract
7.2.3 Automated DNA Isolation
7.3 Storage Technology: Sustainability, Easy Sample Tracking, and Added Security
7.3.1 Dry State, Room Temperature Storage Eliminates the Need for Expensive, Energy-Consuming Freezers
7.3.2 Ultra-Low Temperature Freezers: Is Their Use Declining?
7.3.3 Cryopreservation: Mechanical vs. Liquid/ Vapour Phase Nitrogen
7.3.4 Automated Storage and Retrieval Systems: Essential Technology
7.3.5 RFID and Tagging Technology: Advantages over Barcodes
7.4 Software for Biobanks
7.4.1 Laboratory Information Management System (LIMS): Unmet Needs in the Market Remain, Despite Recent Advances
7.4.2 LIMS Functions
7.5 Consumables: High Quality Required for Effective Sample Management
7.5.1 Addressing Sample Storage and Tracking Issues
7.6 Biobanking Services: Storage, Management and Transport of Biologic Samples for a Fee
8. Leading Companies in the Biobanking Market
8.1 The Differing Business Models of Biobanking Companies: Sourcing vs. Storing
8.2 Commercial Biobanks for Research Purposes in 2017
8.2.1 Tissue Solutions: A Virtual Biobank with a Global Presence
8.2.1.1 An Overview of the Products and Services Offered by Tissue Solutions
8.2.1.2 Banked Samples Occur in Many Formats
8.2.1.3 Prospective Tissue Collection for Hard-to-Find Samples
8.2.1.4 Fresh Samples from Surgical Resections are in High Demand
8.2.1.5 Freshly Isolated Human Cells are a Valuable Research Tool
8.2.1.6 FDA/EMA Panel of Normal Tissues
8.2.1.7 Strengths, Capabilities and the Future Outlook for Tissue Solutions
8.2.2 Asterand Bioscience is now Part of Stemgent
8.2.2.1 Asterand’s Products and Services: XpressBANK, BioSpoke and PhaseZERO
8.2.2.2 The Future Outlook for Asterand
8.2.3 Biopta: Human Tissue Provider Now Acquired by Japanese Company ReproCELL
8.2.3.1 Services from Biopta: A Variety of Lab Services and Fresh Tissue Sample Procurement
8.2.3.2 The First Catalogue of Assays Based on Human Functional Tissues
8.2.3.3 The Future Outlook for Biopta: Fresh Tissue Will Be in Demand
8.2.4 BioServe: One of the World’s Largest Commercial Biorepositories
8.2.4.1 BioServe Offers a Comprehensive List of Services: Biobanking, Sourcing and Preclinical Molecular Services
8.2.4.2 The Future Outlook for BioServe
8.2.5 Coriell Institute for Medical Research: Reportedly the Largest Biobank in the World
8.2.5.1 Features of and Recent Developments at Coriell Biobank
8.2.5.2 Future Outlook for the Coriell Biobank
8.3 Prominent Biobanks for Therapeutic Use in 2017
8.3.1 Cord Blood America: Expansion into the Emerging Markets Apparently Stalled, Strategic Alternatives Being Considered
8.3.2 Cryo-Cell International: The First Private Cord Blood Bank in the Market
8.3.3 Cryo-Save’s Educational Programme Benefits Company’s Growth
8.3.4 China Cord Blood Corp: The Only Cord Blood Bank in China with Multiple Licences Is Under a New Owner
8.3.5 LifebankUSA: Acquisition from Human Longevity Inc Will Potentially Drive Growth
8.3.6 ViaCord: More Blood Units Released for Therapy than Any Other Family Bank
8.3.7 Cord Blood Registry: The World’s Largest Newborn Stem Cell Company Will Be Promoted By New Parent Company
8.3.8 Biogenea Pharmaceuticals: A Comprehensive Offering of Stem Cell Banking Services across the Balkan Peninsula
8.3.9 StemLife is Reportedly Facing Challenges due to Government Regulations in Malaysia
8.3.10 Future Health Biobank: A Strong Market Presence Owing to International Operations
8.3.11 Caladrius Biosciences (formerly NeoStem): More Focus on Cell Therapy Than Stem Cell Banking
8.3.12 Precious Cells is Well Positioned to Take Advantage of the Growing Demand in India
9. Qualitative Analysis of the Biobanking Market 2017 to 2027
9.1 Industry Trends
9.1.1 The Growing Demand for Biobank Resources for Research
9.1.2 The Establishment of Biobanking Networks
9.1.2.1 BBMRI: The Most Extensive Biobank Network
9.1.3 Virtual Biobanks: Connecting a Fragmented Industry
9.1.4 Commercial Biobanks as Intermediaries: New Resources for Research
9.1.5 Automated Biobanking Has Become Imperative
9.1.6 Increasing Uptake of LIMS
9.1.7 Green Banking – Becoming More Energy Efficient
9.2 The Strengths and Weaknesses of the Biobanking Market in 2017
9.2.1 HBS are Valuable Resources for R&D
9.2.2 Governmental Support for Biobanking Forms a Strength of that Industry
9.2.3 Development of Potential Novel Stem Cell Therapies has Increased Public Awareness of Stem Cell Banking
9.2.4 The Effect of Big Data on Biobanking
9.2.5 Insufficient Accessible Numbers of High Quality Biospecimens
9.2.6 Biobanks are Fragmented and Uncoordinated
9.2.7 Lack of Standardisation is a Weakness of the Industry
9.2.8 Lack of Public Awareness Limits Number of Donors
9.2.9 Lack of Engagement with Public Health Services Limits the Stem Cell Banking Market
9.3 Opportunities and Threats Facing the Biobanking Market, 2017 to 2027
9.3.1 Increasing Use of Biobanked Specimens in Genome-Wide Association Studies (GWAS)
9.3.2 Increasing Demand for Biobanked Samples for Preclinical Research
9.3.3 Biobanking Networks as a Basis for Personalised Medicine
9.3.4 Options for Adult Stem Cell Banking Mean an Increasing Target Population for Private Stem Cell Banks
9.3.5 Even With Governmental Funding, Biobanks Must Become Self-Sufficient to Thrive Long-Term
9.3.6 Public Concerns over Confidentiality and Security Threaten Availability of Donors
9.3.7 Limitations Surrounding Informed Consent
9.4 Social, Technological, Economic and Political Factors (STEP) Influencing the Biobanking Industry, 2017 to 2027
10. Conclusions from Our Research and Analysis
10.1 World Biobanking Market 2017 to 2027: High Revenue Growth Predicted
10.2 Biobanking for Research 2017 to 2027: The Value of Biobanked Specimens is Increasingly Recognised
10.3 Biobanking for Therapeutic Use 2017 to 2027: Rapid Expansion in Adult Stem Cell Banking
10.4 The Leading National Markets: High Sales Growth Worldwide
10.5 Current and Future Trends in Biobanking
10.5.1 Increasing Demand for Biobanked Samples – Increasing Revenue
10.5.2 Improving Biobanking Infrastructure – Growth Driver and a Need for Strategic Planning for Sustainability
10.5.3 Marked Challenges, but Opportunities for Expansion
11. Glossary
Associated Visiongain Reports
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form
List of Figures
Figure 1.1 Global Biobanking Industry Segmentation Overview, 2017
Figure 2.1 Processes Involved in Biobanking, 2017
Figure 2.2 The Classification of Biobanks, 2017
Figure 3.1 Breakdown of the Biobanking Industry by Research vs. Therapeutics: Revenue ($bn) and Market Share (%), 2017
Figure 3.2 Breakdown of the Biobanking Industry by Research vs. Therapeutics: Market Shares (%), 2022
Figure 3.3 Breakdown of the Biobanking Industry by Research vs. Therapeutics: Market Shares (%), 2027
Figure 3.4 Biobanking for Medicine: Overarching Revenue Forecast ($bn), 2017 to 2027
Figure 3.5 The No. of Samples Stored in Biobanks by Purpose: Overall World Forecast, No. Of Samples (m), 2017 to 2027
Figure 3.6 Biobanking for Medicine by Sector: Grouped Forecasts, Revenue ($bn), 2017 to 2027
Figure 3.7 Biobanking Market for Research: Revenue Forecast ($bn), 2017 to 2027
Figure 3.8 Biobanking for Research: Drivers and Restraints, 2017 to 2027
Figure 3.9 Biobanking for Therapeutic Use: Revenue Forecast ($bn), 2017 to 2027
Figure 3.10 Biobanking for Therapeutic Use: Drivers and Restraints, 2016 to 2027
Figure 4.1 The Biobanking for Research Market by Tissue Type: Market Share (%), 2017
Figure 4.2 Biobanking for Research by Tissue Type: Market Shares (%), 2022
Figure 4.3 Biobanking for Research by Tissue Type: Market Shares (%), 2027
Figure 4.4 Biobanking for Research by Tissue Type: Grouped Revenue Forecasts ($bn), 2017 to 2027
Figure 4.5 Biobanking for Research: Market Drivers and Restraints, 2017 to 2027
Figure 4.6 Number of Research Samples Banked: Overall World Forecast, No. of Samples (m), 2017 to 2027
Figure 4.7 The Human Tissue Banking Market: Revenue Forecast ($bn), 2017 to 2027
Figure 4.8 Human Tissue Banking for Research: Market Drivers and Restraints, 2017 to 2027
Figure 4.9 The Commercial vs. Public Sector Human Tissue Banking Market: Market Shares (%), 2017
Figure 4.10 The Commercial vs. Public Sector Human Tissue Banking Market: Market Shares (%), 2022
Figure 4.11 The Commercial vs. Public Sector Human Tissue Banking Market: Market Share (%), 2027
Figure 4.12 The Human Tissue Banking Market by Subsector: Revenue Forecasts ($bn), 2017 to 2027
Figure 4.13 Commercial Human Tissue Banking: Revenue Forecast ($bn), 2017 to 2027
Figure 4.14 Public Sector Human Tissue Banking: Revenue Forecast ($bn), 2017 to 2027
Figure 4.15 The Stem Cell Banking Market for Research: Revenue Forecast ($bn), 2017 to 2027
Figure 4.16 Stem Cell Banking for Research: Market Drivers and Restraints, 2017 to 2027
Figure 4.17 Banking of Other Biologic Specimens for Research: Revenue Forecast ($bn), 2017 to 2027
Figure 4.18 Biobanking of Other Biologic Specimens for Research: Market Drivers and Restraints, 2016 to 2027
Figure 5.1 Biobanking for Therapeutic Use by Stem Cell Type: Market Shares (%), 2017
Figure 5.2 Biobanking for Therapeutic Use by Stem Cell Type: Market Shares (%), 2022
Figure 5.3 Biobanking for Therapeutic Use by Stem Cell Type: Market Shares (%), 2027
Figure 5.4 Biobanking for Therapeutic Use by Stem Cell Type: Grouped Revenue Forecasts ($bn), 2017 to 2027
Figure 5.5 The Number of Stem Cell Samples Banked for Therapeutic Use (m): Forecast 2017 to 2027
Figure 5.6 The Stem Cell Banking Market for Future Therapeutic Use: Drivers and Restraints, 2017 to 2027
Figure 5.7 The Umbilical Cord Banking Market: Revenue Forecast ($bn), 2017 to 2027
Figure 5.8 The Umbilical Cord Blood Banking Market: Drivers and Restraints, 2017 to 2027
Figure 5.9 The Adult Stem Cell Banking Market: Revenue Forecast ($bn), 2017 to 2027
Figure 5.10 The Adult Stem Cell Banking Market: Drivers and Restraints, 2017 to 2027
Figure 6.1 The Leading National Biobanking Markets: Market Shares (%), 2017
Figure 6.2 The Leading National Markets: Grouped Revenue Forecasts ($bn), 2017 to 2027
Figure 6.3 The Leading National Markets: Market Share (%), 2022
Figure 6.4 The Leading National Markets: Market Share (%), 2027
Figure 6.5 Biobanking for Medicine in the US: Revenue Forecast ($bn), 2017 to 2027
Figure 6.6 Driving and Restraining Factors of the US Biobanking Market, 2017 to 2027
Figure 6.7 The Leading European Markets for Biobanking: Grouped Revenue Forecasts ($bn), 2017 to 2027
Figure 6.8 Biobanking in the Leading European Countries: Driving and Restraining Factors, 2017 to 2027
Figure 6.9 The German Biobanking Industry: Revenue Forecast ($bn), 2017 to 2027
Figure 6.10 The French Biobanking Industry: Revenue Forecast ($bn), 2017 to 2027
Figure 6.11 The Italian Biobanking Industry: Revenue Forecast ($bn), 2017 to 2027
Figure 6.12 The UK Biobanking Industry: Revenue Forecast ($bn), 2017 to 2027
Figure 6.13 The Spanish Biobanking Industry: Revenue Forecast ($bn), 2017 to 2027
Figure 6.14 The Netherlands Biobanking Industry: Revenue Forecast ($bn), 2017 to 2027
Figure 6.15 The Japanese Biobanking Industry: Revenue Forecast ($bn), 2017 to 2027
Figure 6.16 Driving and Restraining Factors Influencing the Japanese Biobanking Industry, 2017 to 2027
Figure 6.17 The Biobanking Industry in the BRIC Countries: Grouped Revenue Forecasts ($bn), 2017 to 2027
Figure 6.18 Driving and Restraining Factors of the Biobanking Industry in the BRIC Countries, 2017 to 2027
Figure 6.19 The Chinese Biobanking Industry: Revenue Forecast ($bn), 2017 to 2027
Figure 6.20 The Indian Biobanking Industry: Revenue ($bn) Forecast, 2017 to 2027
Figure 6.21 The Brazilian Biobanking Market: Revenue Forecast ($bn), 2017 to 2027
Figure 6.22 The Russian Biobanking Industry: Revenue Forecast ($bn), 2017 to 2027
Figure 7.1 Structure of the Biobanking Industry: Biobanking-Associated Market, Biobanks and End Users, 2017
Figure 7.2 The Basic Function of LIMS
Figure 8.1 Biobanking Business Model: Commercial Sourcing of Biological Samples, 2017
Figure 8.2 Business Model: Commercial Banking of Biological Samples, 2017
Figure 8.3 China Cord Blood Corp: Revenue ($m), 2014 to 2016
Figure 8.4 StemLife: Comparison of Revenue ($m), 2015 and 2016
Figure 10.1 The Global Biobanking Market by Industry Sector: Comparison of Revenues ($bn), 2017, 2022 and 2027
Figure 10.2 Biobanking for Research by Sample Type: Comparison of Revenues ($bn), 2017, 2022 and 2027
Figure 10.3 Stem Cell Banking for Therapeutic Use by Stem Cell Type: Comparison of Revenues ($bn), 2017, 2022 and 2027
Figure 10.4 Leading Regional Markets for Biobanking: Comparison of Revenues ($bn), 2017, 2027 and 2027
List of Tables
Table 1.1 Biobanking for Medicine by Sector: Grouped Forecasts, Revenue ($bn), Annual Growth (%), CAGR (%), 2017 to 2027 (redacted)
Table 2.1 Prominent Population-Based Biobanks, 2017
Table 2.2 Prominent Disease-Based Biobanks, 2017
Table 2.3 Guidelines and Recommendations for Biobanks, 2017
Table 2.4 Laws and Other Regulations for Biobank-Based Research by Country/ Organisation 2017
Table 2.5 Pharmaceutical and Biotechnology Companies with In-House Biobanks, 2017
Table 3.1 Breakdown of the Biobanking Industry by Research vs. Therapeutics: Revenue ($bn) and Market Share (%), 2017
Table 3.2 Biobanking for Medicine: Research vs. Therapeutics in 2022 and 2027
Table 3.3 Biobanking for Medicine: Overall World Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2017 to 2027
Table 3.4 The No. of Samples Stored in Biobanks by Purpose: Overall World Forecast No. Of Samples (m), Annual Growth (%), CAGR (%), 2017 to 2027
Table 3.5 Biobanking for Medicine by Sector: Grouped Forecasts, Revenue ($bn), Annual Growth (%), CAGR (%), 2017 to 2027
Table 3.6 Biobanking Market for Research Forecast: Revenue ($bn), Market Share (%), Annual Growth (%), CAGR (%), 2017 to 2027
Table 3.7 Biobanking for Therapeutic Use Forecast: Revenue ($bn), Market Share (%), Annual Growth (%), CAGR (%), 2016 to 2027
Table 4.1 The Biobanking for Research Market by Tissue Type: Revenues ($bn) and Market Shares (%), 2017
Table 4.2 Biobanking for Research by Tissue Type: A Comparison of Revenues ($bn) and Market Shares (%), 2022 and 2027
Table 4.3 Biobanking for Research by Tissue Type: Grouped Forecasts, Revenue ($bn), Annual Growth (%), CAGR (%), 2017 to 2027
Table 4.4 Number of Research Samples Banked: Overall World Forecast, No. of Samples (m), Annual Growth (%), CAGR (%), 2017 to 2027
Table 4.5 The Human Tissue Banking Market Forecast: Revenue ($bn), Market Share (%) Annual Growth (%), CAGR (%), 2017 to 2027
Table 4.6 The Commercial vs. Public Sector Human Tissue Banking Market: Comparison of Revenues ($bn) and Market Share (%), 2017, 2022 and 2027
Table 4.7 Commercial Human Tissue Banking Forecast, Revenue ($bn) Annual Growth (%), CAGR (%), 2017 to 2027
Table 4.8 Commercial Human Tissue Banking Forecast: Revenue ($bn), Market Share (%), Annual Growth (%), CAGR (%), 2017 to 2027
Table 4.9 Prominent Commercial Human Tissue Banks, 2017
Table 4.10 Public Sector Human Tissue Banking Forecast: Revenue ($bn), Market Share (%) Annual Growth (%), CAGR (%), 2017 to 2027
Table 4.11 Prominent Public-Funded Human Tissue Banks, 2016
Table 4.12 The Stem Cell Banking Market for Research Forecast: Revenue ($bn), Market Share (%), Annual Growth (%), CAGR (%), 2017 to 2027
Table 4.13 Prominent Stem Cell Banks Serving the Research Community, 2017
Table 4.14 Banking of Other Biologic Specimens for Research Forecast: Revenue ($bn), Market Share (%), Annual Growth (%), CAGR (%), 2017 to 2027
Table 4.15 Prominent Biobanks Storing Other Biologic Samples, 2017
Table 5.1 Biobanking for Therapeutic Use by Stem Cell Type: Market Share (%), 2017
Table 5.2 Biobanking for Therapeutic Use by Stem Cell Type: Comparison of Revenues ($bn) and Market Share (%), 2022 and 2027
Table 5.3 Number of Research Samples Banked: Overall World Forecast, No. of Samples (m), Annual Growth (%), CAGR (%), 2017 to 2027
Table 5.5 Prominent Public and Private Cord Blood Banks, 2017
Table 5.6 The Umbilical Cord Banking Market Forecast: Revenue ($bn), Market Share (%), Annual Growth (%), CAGR (%), 2017 to 2027
Table 5.7 Prominent Companies in the Adult Stem Cell Banking Industry, 2017
Table 5.8 The Adult Stem Cell Banking Market Forecast: Revenue ($bn), Market Share (%), Annual Growth (%), CAGR (%), 2017 to 2027
Table 6.1 Breakdown of BBMRI Network Directory Members by Country, 2017
Table 6.2 The Leading National Biobanking Markets: Comparison of Revenues ($bn) and Market Shares (%), 2017
Table 6.3 Leading National Markets Grouped Forecasts: Revenue ($bn), Annual Growth (%), CAGR (%), 2017 to 2027
Table 6.4 Leading National Markets: Comparison of Market Share (%), 2017, 2022 and 2027
Table 6.5 Biobanking for Medicine in the US Forecast: Revenue ($bn), Market Share (%), Annual Growth (%), CAGR (%), 2017 to 2027
Table 6.6 The Leading European Markets for Biobanking Grouped Forecasts: Revenue ($bn), Market Share (%) Annual Growth (%), CAGR (%), 2017 to 2027
Table 6.7 Examples of Biobanking Initiatives Funded by the European Commission, 2016
Table 6.8 The German Biobanking Industry Forecast: Revenue ($bn), Market Share (%), Annual Growth (%), CAGR (%), 2017 to 2027
Table 6.9 The French Biobanking Industry Forecast: Revenue ($bn), Market Share (%), Annual Growth (%), CAGR (%), 2017 to 2027
Table 6.10 The Italian Biobanking Industry Forecast: Revenue ($bn), Market Share (%), Annual Growth (%), CAGR (%), 2017 to 2027
Table 6.11 The United Kingdom Biobanking Industry Forecast: Revenue ($bn), Market Share (%), Annual Growth (%), CAGR (%), 2017 to 2027
Table 6.12 The Spanish Biobanking Industry Forecast: Revenue ($bn), Market Share (%), Annual Growth (%), CAGR (%), 2017 to 2027
Table 6.13 Prominent Clinical and Population Biobanks in the Netherlands, 2017
Table 6.14 The Netherlands Biobanking Industry Forecast: Revenue ($bn), Market Share (%), Annual Growth (%), CAGR (%), 2017 to 2027
Table 6.15 The Japanese Biobanking Industry Forecast: Revenue ($bn), Market Share (%), Annual Growth (%), CAGR (%), 2017 to 2027
Table 6.17 The Chinese Biobanking Industry Forecast: Revenue ($bn), Market Share (%), Annual Growth (%), CAGR (%), 2017 to 2027
Table 6.18 The Indian Biobanking Industry Forecast: Revenue ($bn), Market Share (%), Annual Growth (%), CAGR (%), 2017 to 2027
Table 6.19 Prominent Research Biobanks in India, 2017
Table 6.20 The Brazilian Biobanking Industry Forecast: Revenue ($bn), Market Share (%), Annual Growth (%), CAGR (%), 2017 to 2027
Table 6.21 The Russian Biobanking Industry Forecast: Revenue ($bn), Market Share (%), Annual Growth (%), CAGR (%), 2017 to 2027
Table 7.1 Prominent Companies Providing Automated Liquid Handling Technology, 2017
Table 7.2 Prominent Companies Providing Room Temperature Storage Solutions, 2017
Table 7.3 Prominent Companies Providing Ultra-Low Temperature Freezers (-80โC), 2017
Table 7.4 Mechanical Freezing vs. Liquid Nitrogen: Comparison of Advantages and Disadvantages, 2017
Table 7.5 Prominent Companies Providing Cryogenic Storage Solutions, 2017
Table 7.6 Prominent Providers of Automated Biobanking Systems, 2017
Table 7.7 Major Vendors in the LIMS Market, 2017
Table 7.8 Prominent Vendors of Consumables for Biobanking, 2017
Table 7.9 Prominent Biorepository Service Providers, 2017
Table 8.1 Prominent Players in the Biobanking Industry for Research, 2017
Table 8.2 Prominent Companies in the Stem Cell Banking Industry for Therapeutic Use, 2017
Table 8.3 China Cord Blood Corp: Revenue ($m), Total Units Stored for Subscribers, and No. Of New Subscribers, 2014 to 2016
Table 8.4 StemLife: Comparison of Revenue ($m) between 2015 and 2016
Table 9.1 Strengths and Weaknesses of the Biobanking Industry, 2017
Table 9.2 Opportunities and Threats Facing the Biobanking Industry, 2016 to 2027
Table 9.3 Social, Technological, Economic and Political (STEP) Forces Influencing the Biobanking Industry, 2016 to 2027
